Journal of Hepatology
Volume 39 , Pages 59-63 , 2003

Hepatitis B virus and hepatocellular carcinoma

References 

  1. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19:271–285
  2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153–156
  3. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al.  Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology. 1995;21:77–82
  4. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, et al.  Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000;47:131–136
  5. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al.  Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost-effectiveness analysis. Gut. 2001;48:251–259
  6. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al.  Clinical Management of Hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL Conference. J Hepatol. 2001;35:421–430
  7. Beasley RP. Hepatitis B virus as the etiologic agent in hepatocellular carcinoma. Hepatology. 1982;2:21–26s
  8. Chang MH, Chen DS. Prospects for hepatitis B virus eradication and control of hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol. 1999;13:511–517
  9. Okuda K. Hepatocellular carcinoma. J Hepatol. 2000;32:225–237
  10. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely ‘occult’?. Hepatology. 2001;34:194–203
  11. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet. 1981;2:1129–1133
  12. Sakuma K, Saitoh N, Kasai M, Jitsukawa H, Yoshino I, Yamaguchi M, et al.  Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study. Hepatology. 1988;8:1642–1646
  13. McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F, et al.  Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology. 2000;32:842–846
  14. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et al.  Natural history and prognostic factors for chronic hepatitis type B. Gut. 1991;32:294–298
  15. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology. 1995;22:432–438
  16. Jackson PE, Groopman JD. Aflatoxin and liver cancer. Baillieres Best Pract Res Clin Gastroenterol. 1999;13:545–555
  17. Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet. 1991;338:1356–1359
  18. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al.  Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med. 1997;336:1855–1859
  19. Kensler TW, He X, Otieno M, Egner PA, Jacobson LP, Chen B, et al.  Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol Biomarkers Prev. 1998;7:127–134
  20. Wang JS, Shen X, He X, Zhu YR, Zhang BC, Wang JB, et al.  Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J Natl Cancer Inst. 1999;91:347–354
  21. Brechot C, Gozuacik D, Murakami Y, Paterlini-Brechot P. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol. 2000;10:211–231
  22. Chen PJ, Chen DS. Hepatitis B virus infection and hepatocellular carcinoma: molecular genetics and clinical perspectives. Semin Liver Dis. 1999;19:253–262
  23. Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med. 1981;305:1067–1073
  24. Halliwell B. Oxygen and nitrogen are pro-carcinogens. Damage to DNA by reactive oxygen, chlorine and nitrogen species: measurement, mechanism and the effects of nutrition. Mutat Res. 1999;443:37–52
  25. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, et al.  Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology. 2001;120:1763–1773
  26. Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol. 2000;10:185–200
  27. Baffis V, Shrier I, Sherker AH, Szilagyi A. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann Intern Med. 1999;131:696–701
  28. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol. 2001;34:593–602
  29. Prorok PC. Epidemiologic approach for cancer screening. Problems in design and analysis of trials. Am J Pediatr Hematol Oncol. 1992;14:117–128
  30. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med. 1996;101:422–434
  31. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998;27:273–278
  32. Sherman M. Alphafetoprotein: an obituary. J Hepatol. 2001;34:603–605
  33. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al.  Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34:570–575
  34. Nakashima T, Kojiro M. Pathologic characteristics of hepatocellular carcinoma. Semin Liver Dis. 1986;6:259–266
  35. Lok AS, Lai CL. Alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology. 1989;9:110–115
  36. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in HCC. Hepatology. 2002;35:519–524
  37. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002;122:1609–1619
  38. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al.  Results of surgical and non-surgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology. 2000;32:1224–1229
  39. Llovet JM, Real MI, Montanya X, Planas R, Coll S, Aponte AJ, et al.  Arterial embolization, chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002;359:1734–1739
  40. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–1171

PII: S0168-8278(03)00140-5

doi: 10.1016/S0168-8278(03)00140-5

Journal of Hepatology
Volume 39 , Pages 59-63 , 2003

Article Tools

* Image Usage & Resolution